Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
as soon as is submitted to ZB.
Saxagliptin, alogliptin, and cardiovascular outcomes.
N. Engl. J. Med. 370, 483-484 (2014)
To the Editor: Besides showing futility in the use of dipeptidyl peptidase 4 (DPP-4) inhibitors to reduce cardiovascular outcomes, the studies by Scirica et al.(1) and White et al.(2) (Oct. 3 issue) have raised concerns regarding increased rates of heart failure associated with these agents. The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 (SAVOR-TIMI 53) trial, reported by Scirica et al., showed a 27% increase in hospitalization for heart failure among patients with diabetes who received saxagliptin as compared with patients with diabetes who received placebo (3.5% vs. 2.8%; hazard ...
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Letter to the Editor
ISSN (print) / ISBN
0028-4793
e-ISSN
1533-4406
Quellenangaben
Volume: 370,
Issue: 5,
Pages: 483-484
Publisher
Massachusetts Medical Society (MMS)
Publishing Place
Waltham
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes Research Type 1 (IDF)